Literature DB >> 31928104

Benefits and limitations of continuous glucose monitoring in type 1 diabetes.

Jenine Y Stone1,2, Timothy S Bailey1.   

Abstract

Introduction: Type 1 diabetes (T1D) is a chronic condition characterized by a complete deficiency in insulin production. Optimal management requires constant knowledge of glucose levels for safe and effective insulin administration. Self-monitoring of blood glucose (SMBG) using capillary blood glucose meters is cumbersome and provides limited information to guide management. Continuous glucose monitoring (CGM) technology addresses many of these gaps, but itself has limitations which have prevented people with diabetes and their clinicians from fully embracing this technology. This review covers the benefits and limitations of CGM use, and looks toward future application of this technology in the management of T1D.Areas covered: Impact of CGM on physical and psychosocial outcomes in people with T1D. Barriers to CGM uptake. Integration with insulin pumps and other technologies. Opportunities for future application.Expert opinion: CGM technology will be utilized by the majority of people with T1D and increasing numbers of people with type 2 diabetes due to improved insurance coverage and easier-to-use systems. Its use as part of artificial pancreas systems will add further utility, as it will help to protect from both hypoglycemia and hyperglycemia. People with diabetes will spend more time in range and experience fewer acute and chronic complications.

Entities:  

Keywords:  CGM; SMBG; Type 1 diabetes; Type 2 diabetes; barriers; benefits; continuous glucose monitoring; glucose management; limitations; self-monitoring of blood glucose; technology

Mesh:

Substances:

Year:  2020        PMID: 31928104     DOI: 10.1080/17446651.2020.1706482

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  5 in total

1.  Improvement in Mean CGM Glucose in Young People with Type 1 Diabetes During 1 Year of the COVID-19 Pandemic.

Authors:  Tara Kaushal; Liane Tinsley; Lisa K Volkening; Louise Ambler-Osborn; Lori Laffel
Journal:  Diabetes Technol Ther       Date:  2021-10-13       Impact factor: 6.118

Review 2.  Glucose biosensors in clinical practice: principles, limits and perspectives of currently used devices.

Authors:  Salvatore Andrea Pullano; Marta Greco; Maria Giovanna Bianco; Daniela Foti; Antonio Brunetti; Antonino S Fiorillo
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

3.  Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems Compared with the Point-of-Care or Laboratory-Based Measurements: An Observational Study.

Authors:  Ayman A Al Hayek; Samia H Sobki; Abdulghani H Al-Saeed; Wael M Alzahrani; Mohamed A Al Dawish
Journal:  Diabetes Ther       Date:  2022-03-20       Impact factor: 3.595

4.  Temperature Correction to Enhance Blood Glucose Monitoring Accuracy Using Electrical Impedance Spectroscopy.

Authors:  Ye Sung Lee; Minkook Son; Alexander Zhbanov; Yugyung Jung; Myoung Hoon Jung; Kunsun Eom; Sung Hyun Nam; Jongae Park; Sung Yang
Journal:  Sensors (Basel)       Date:  2020-10-31       Impact factor: 3.576

5.  An analytical approach to determine the optimal duration of continuous glucose monitoring data required to reliably estimate time in hypoglycemia.

Authors:  Nunzio Camerlingo; Martina Vettoretti; Andrea Facchinetti; Giovanni Sparacino; Julia K Mader; Pratik Choudhary; Simone Del Favero
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.